The Revance Therapeutics Inc (RVNC) CEO Sells $401,159.55 in Stock

The Revance Therapeutics Inc (RVNC) CEO Sells $401,159.55 in Stock

L Daniel Browne also recently made the following trade(s):

Revance Therapeutics Inc (NASDAQ:RVNC) CEO L Daniel Browne sold 19,713 shares of the company’s stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $20.35, for a total value of $401,159.55. Following the sale, the chief executive officer now owns 183,932 shares of the company’s stock, valued at $3,743,016.20. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Shares of Revance Therapeutics Inc (NASDAQ:RVNC) traded up 5.73% on Friday, reaching $24.90. The company’s stock had a trading volume of 354,051 shares. The company’s market cap is $753.80 million. The company’s 50 day moving average price is $21.09 and its 200 day moving average price is $20.22. Revance Therapeutics Inc has a 12-month low of $12.35 and a 12-month high of $24.90. Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.10. Revance Therapeutics had a negative net margin of 28,187.33% and a negative return on equity of 37.31%. The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.07 million. During the same period in the previous year, the business posted ($0.71) EPS. The firm’s revenue was up .0% on a year-over-year basis. Analysts forecast that Revance Therapeutics Inc will post ($3.92) EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the company. Parametric Portfolio Associates LLC raised its stake in Revance Therapeutics by 5.9% in the first quarter. Parametric Portfolio Associates LLC now owns 27,401 shares of the biopharmaceutical company’s stock worth $570,000 after buying an additional 1,524 shares during the period. Swiss National Bank raised its stake in Revance Therapeutics by 6.8% in the first quarter. Swiss National Bank now owns 32,850 shares of the biopharmaceutical company’s stock worth $683,000 after buying an additional 2,100 shares during the period. Essex Investment Management Co. LLC raised its stake in Revance Therapeutics by 8.2% in the first quarter. Essex Investment Management Co. LLC now owns 98,684 shares of the biopharmaceutical company’s stock worth $2,053,000 after buying an additional 7,456 shares during the period. Acadian Asset Management LLC purchased a new stake in Revance Therapeutics during the first quarter worth $735,000. Finally, Candriam Luxembourg S.C.A. raised its stake in Revance Therapeutics by 82.1% in the first quarter. Candriam Luxembourg S.C.A. now owns 122,000 shares of the biopharmaceutical company’s stock worth $2,538,000 after buying an additional 55,000 shares during the period.

A number of equities analysts have issued reports on RVNC shares. Aegis reaffirmed a “buy” rating and issued a $28.00 target price on shares of Revance Therapeutics in a report on Monday, May 1st. Zacks Investment Research upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $32.60. Revance Therapeutics Company Profile

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:RVNC”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment